Sequenom and SensiGen Expand Global Alliance
Under the expanded agreement, in addition to commercializing SensiGen's advanced test for human papillomavirus (HPV) exclusively on Sequenom's MassARRAY(R) platform, SensiGen will also be the exclusive provider of MassARRAY platform-based assays for SensiGen's newly developed Chronic Kidney Disease (CKD) and Lupus tests. Sequenom will exclusively supply platform technology and reagents used for commercializing SensiGen's proprietary tests. The expanded agreement also provides Sequenom with the future right to a minority equity interest in SensiGen. Financial terms of the alliance were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.